Not registered yet? Get a free account.
Sign UpYou're about to leave our website and go to an external link. Are you sure?
Nextgen In-Vitro Diagnostics Private Limited, is an unlisted private company incorporated on 24 April, 2015. It is classified as a private limited company and is located in , Delhi. It's authorized share capital is INR 4.05 cr and the total paid-up capital is INR 2.04 cr.
Nextgen In-Vitro Diagnostics's operating revenue range is INR 1 cr - 100 cr for the financial year ending on 31 March, 2024. It's book networth has decreased by 69.92%.
Read more
** All rupee values in INR lacs.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
** Delivery timelines are on best-effort basis during working hours. Filings 3-4 hours. Reports 24-48 hours.
* INR 349 for 20+ credits purchase
1 credit = one company dashboard
| State | Type | Address |
|---|
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Varun Chopra
Shareholder
|
01044311 | 11 years |
| Director | Sushil Mehta
Shareholder
|
01010831 | 9 years |
| Director | Ashok Kumar Jain
Shareholder
|
05332592 | 6 years |
| Director | Pankaj Krishna | 08952207 | 2 years |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
As per information available, the company has no registered charges.
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| GLAZED PATISSERIE PRIVATE LIMITED |
Active
|
1.0 L | 1 | Haryana |
| ALVED PHARMA FOODS PRIVATE LIMITED |
Amalgamated
|
97.9 L | 1 | Tamil Nadu |
| AYURVET LIMITED |
Active
|
9.4 Cr | 1 | Delhi |
| J.T. BAKER CHEMICALS PRIVATE LIMITED |
Strike Off
|
3.0 Cr | 2 | Maharashtra |
| PALM SPRING WELFARE FOUNDATION |
Active
|
1,000.0 | 1 | |
| QUNU LABS PRIVATE LIMITED |
Active
|
9.9 Cr | 1 | Karnataka |
| ZENEX ANIMAL HEALTH INDIA PRIVATE LIMITED |
Active
|
2,513.1 Cr | 1 | Gujarat |
| AYURVET LIMITED |
Active
|
9.4 Cr | 1 | Gujarat |
| KAPS CHOPS HOSPITALITY PRIVATE LIMITED |
Strike Off
|
5.0 L | 1 | Delhi |
| TROPICAL BOVINE GENETICS PRIVATE LIMITED |
Active
|
6.5 Cr | 1 | Andhra Pradesh |
| QUNU SERVICES PRIVATE LIMITED |
Strike Off
|
1.0 L | 1 | Delhi |
| HEALCURE SERVICE PRIVATE LIMITED |
Active
|
1.0 L | 1 | Haryana |
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| BIOHOUSE SOLUTIONS PRIVATE LIMITED | Delhi | 2009 | ₹ 2.0 Cr |
Read more
The incorporation date of NEXTGEN IN-VITRO DIAGNOSTICS PRIVATE LIMITED is 24 April, 2015
The authorized share capital of NEXTGEN IN-VITRO DIAGNOSTICS PRIVATE LIMITED is INR ₹ 4.0 Cr.
The paid-up capital of NEXTGEN IN-VITRO DIAGNOSTICS PRIVATE LIMITED is INR ₹ 2.0 Cr.
The registered address of NEXTGEN IN-VITRO DIAGNOSTICS PRIVATE LIMITED is C-1/59 SAFDARJUNG DEVELOPMENT AREA, South Delhi, NEW DELHI, Delhi, India, 110016 - 110016
The CIN number of NEXTGEN IN-VITRO DIAGNOSTICS PRIVATE LIMITED is U33110DL2015PTC279481.